Angiocentric T cell lymphoma is a variant of peripheral T cell lymphoma characterized by an angiocentric and angioinvasive infiltrates, invasion of vascular walls, and occulsion of lumen by atypical lymphoid cells with varying degrees of cytologic atypia. We recently experienced a woman with angiocentric T cell lymphorma, who presented with multiple erythematous nodules of skin, subcutaneous mass on right face and peripheral polyneuropathy. At the skin biopy specimen, we could find angiocentric and angioinvasive infiltrate by atypical lymphoid cells which showed a positive immunohistochemical reaction for CD45RO that is one of the T cell markers and a negative reaction for B cell marker. She was treated with two cycles of combination chemotherapy composed of CVP (cyclophosphamide, vincristine, prednisolone), that resulted in complete remission.
Drug Therapy, Combination ; Female ; Humans ; Lymphocytes ; Lymphoma, T-Cell* ; Lymphoma, T-Cell, Peripheral ; Polyneuropathies* ; Skin ; Vincristine

Subcutaneous panniculitis-like T cell lymphoma (SPTL) is a distinctive cutaneous lymphoma characterized by an infiltration of subcutaneous tissue by neoplastic T cells, similar to panniculitis. It is well-established that patients who are diagnosed with SPTL usually respond poorly to chemotherapy, showing fatal outcome. As a first line treatment for SPTL, anthracycline-based chemotherapy was most frequently used. For the treatment of SPTL, the efficacy of cyclosporine A has been recently reported in relapsed SPTL after anthracycline-based chemotherapy. However, it is still not clear whether cyclosporine A can be used as a first-line treatment against SPTL. Here, we report a case of SPTL, which achieved complete remission for nine years after first-line cyclosporine A therapy. This study suggests that cyclosporine A can induce a complete long-term remission as a first-line treatment.
Cyclosporine* ; Drug Therapy ; Fatal Outcome ; Humans ; Lymphoma ; Lymphoma, T-Cell* ; Panniculitis ; Subcutaneous Tissue ; T-Lymphocytes

Angiocentric T-cell lymphoma is a subtype of peripheral T-cell lymphoma and histologically characterized by angiocentric and angioinvasive infiltration of lymphoid cells with varying degrees of cytological atypia, leading to angiodestruction. This disease represents the malignant end in the histological spectrum of angiocentric immunproliferative lesions. This malignancy is commonly a disease with considerable morbidity and is often fatal. However, primary cutaneous angiocentric T-cell lymphoma has a tendency to give a favorable prognosis. Epstein-Barr virus can be identified in involved tissue by immunostaining or by in situ hybridization and it is considered significant in the prognosis. We report a case of cutaneous angiocentric T-cell lymphoma, where the Epstein-Barr virus was identified within neoplastic cells. CVP(cyclophosphamide, vincristine, prednisone) chemotherapy was instigated and an initial complete remission was achieved.
Drug Therapy* ; Herpesvirus 4, Human ; In Situ Hybridization ; Lymphocytes ; Lymphoma, T-Cell* ; Lymphoma, T-Cell, Peripheral ; Prognosis ; T-Lymphocytes* ; Vincristine

Cutaneous gamma/delta T-cell lymphoma is an extremely rare and highly aggressive tumor that is often resistant to treatment, such as polychemotherapy and radiotherapy. Due to the complexity of clinical, pathologic, and immunohistochemical features of this disease entity, the physician should perform a careful evaluation; however, treatment should be rapid and aggressive. We present a case of fatal cutaneous gamma/delta T-cell lymphoma of a 55-year old woman who died after recurrence with central nerve system metastasis.
Drug Therapy, Combination ; Female ; Humans ; Lymphoma, T-Cell ; Lymphoma, T-Cell, Cutaneous ; Neoplasm Metastasis ; Recurrence ; T-Lymphocytes

Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma (CSMTCL) is a rare disease constituting 2% of all cutaneous T-cell lymphomas. In most cases, CSMTCL occurs as a solitary lesion and has an indolent course. Here we present a 42-year-old woman with multiple, localized, recurrent, erythematous papules and macules that developed after combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP).
Adult ; Cyclophosphamide ; Doxorubicin ; Drug Therapy, Combination ; Female ; Humans ; Lymphoma ; Lymphoma, T-Cell ; Lymphoma, T-Cell, Cutaneous ; Prednisolone ; Rare Diseases ; T-Lymphocytes ; Vincristine

Primary cutaneous CD30+ lymphoproliferative disorders include primary cutaneous CD30+ (anaplastic) large T cell lymphoma, lymphomatoid papulosis, and borderline cases. These represent a clinical and histologic continuum rather than a separate entity. We report a 39-year-old woman with the clinical features of lymphomatoid papulosis. Histology favored primary CD30+ anaplastic large cell lymphoma. Although she was treated with aggressive combination chemotherapy, the lesions recurred shortly after discontinuation of chemotherapy. She is now regularly followed up without any treatment.
Adult ; Drug Therapy ; Drug Therapy, Combination ; Female ; Humans ; Lymphoma, Large-Cell, Anaplastic ; Lymphoma, T-Cell ; Lymphomatoid Papulosis* ; Lymphoproliferative Disorders

A case of peripheral T-cell lymphoma, large cell type(NIH) is reported. The literature review yielded a rare case report of a malignant lymphoma especially in the even more rare epidural site. The patient's symptoms were relieved by decompressive laminectomy and subtotal removal of mass and combined scheduled chemotherapy with radiotherapy. The pathological examination revealed malignant lymphoma, diffuse, large cell type(NIH) by H & E and immunologic marker analysis.
Biomarkers ; Drug Therapy ; Epidural Space* ; Laminectomy ; Lymphoma ; Lymphoma, T-Cell, Peripheral* ; Radiotherapy

Primary cutaneous CD30 positive large cell lymphoma is a cutaneous T-cell lymphoma with a favorable prognosis, which is characterized by solitary or localized skin lesions with a tendency of spontaneous regression and frequent relapses. On the basis of the morphologic and immunophenotypic similarities between the large atypical cells in lymphomatoid papulosis and the neoplastic cells in primary cutaneous CD30 positive large cell lymphoma as well as their favorable prognosis, these two diseases are now regarded to be in a spectrum of primary cutaneous CD30 positive lymphoproliferative disorder. We present a borderline case of primary cutaneous CD30 positive lymphoproliferative disorder which recurred on the anatomic site different to the primary lesions despite multiple-agent chemotherapy.
Drug Therapy ; Lymphoma ; Lymphoma, T-Cell, Cutaneous ; Lymphomatoid Papulosis ; Lymphoproliferative Disorders* ; Prognosis ; Recurrence ; Skin

Non-Hodgkin's lymphoma can involve the gynecologic tract, most often as a manifestation of systemic involvement. Primary lymphomas of the female genital tract are rare. Most involve the cervix rather than the uterine corpus. All of those previously reported have been B-cell lymphomas, with the exception of several case reports. Primary T-cell lymphoma of the uterine cervix is rare. We describe a rare case of primary cytotoxic T-cell lymphoma of the uterine cervix, Ann Arbor stage IE in a 55-year-old woman. The tumor, incidentally disclosed at gynecological examination, appeared as diffuse cervical enlargement with mucosal erosion. A biopsy was taken and showed diffuse infiltration of variable sized lymphoma cells. Neoplastic cells were positive for LCA, CD3, TIA-1 and consistent with cytotoxic T-cell lymphoma. She was treated with 3 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisolone(CHOP). After chemotherapy, the patient was treated by pelvic external radiation therapy. At present, the patient is well and disease-free.
Biopsy ; Cervix Uteri* ; Cyclophosphamide ; Doxorubicin ; Drug Therapy ; Female ; Gynecological Examination ; Humans ; Lymphoma ; Lymphoma, B-Cell ; Lymphoma, Non-Hodgkin ; Lymphoma, T-Cell* ; Middle Aged ; T-Lymphocytes* ; Vincristine

Cutaneous T-cell lymphoma(CTCL) is a rare cutaneous malignant disease and is typically a disease of older adults. There is no optimal treatment for CTCL, which ranges from topical steroid to systemic chemotherapy. Hence until curative therapy is found, therapies that keep CTCL in check and prevent progression to more advanced lymphoma may be desirable alternatives and may presetve quality of life. Herein we report our experience in treating a stage 11B CTCL patient with triple combination of interferon alfa, oral retinoid, and psoralen plus WA(PWA) therapy.
Adult ; Drug Therapy ; Ficusin ; Humans ; Interferon-alpha* ; Interferons* ; Lymphoma ; Lymphoma, T-Cell, Cutaneous* ; Photochemotherapy* ; Quality of Life ; T-Lymphocytes